AUPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aurinia Pharmaceuticals Inc. (AUPH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite some competitive pressures and a cautious revenue outlook for 2026, the company's strong financial performance, significant profitability improvement, and bullish retail sentiment make it a solid choice.
The stock is showing mixed technical signals. The MACD is positive but contracting, RSI is neutral at 29.395, and moving averages are converging. The stock is trading near its support level of 13.799, with resistance at 14.846. The technical indicators do not show a strong trend but suggest a potential rebound from current levels.
Q4 2025 revenue of $77.1 million, a 29% YoY increase, exceeded expectations.
Adjusted EPS of $1.53 significantly outperformed Wall Street's estimate of $0.
Strong cash position with $398 million in cash and investments.
Retail sentiment is bullish, indicating optimism about the stock.
Initiation of a clinical study for aritinercept indicates potential future growth.
Leerink downgraded the stock to Market Perform, citing competitive pressures and limited visibility into differentiation.
2026 revenue guidance of $315-$325 million is below Wall Street's consensus of $327 million.
Increasing competitive threats in the market could impact future growth.
Aurinia Pharmaceuticals reported exceptional financial results for Q4 2025: Revenue increased by 482.06% YoY to $348.46 million, net income surged 14,651.15% YoY to $210.79 million, and EPS rose 15,200.00% YoY to $1.53. Gross margin also improved to 97.47%, up 7.43% YoY. These results highlight strong profitability and operational efficiency.
Analysts have downgraded the stock to Market Perform from Outperform, with a price target of $16, citing competitive pressures and uncertainty around the long-term potential of its key product, Lupkynis. However, the price target is still above the current price, suggesting some upside potential.
